Opportunities to Apply Targeted Protein Degradation as an Antiviral Strategy
Time: 1:30 pm
day: Post-Conference Focus Day: Next Generation TPD
Details:
- Exploring a paradigm for successful antiviral therapy involves the use of direct-acting antivirals that generally suffer from narrow spectrum activity and rapid evolution of resistance when these agents are used as monotherapies
- Developing antivirals that may better address the genetic diversity across a viral species or multiple species and also more resilient to point mutations that reduce drug-binding
- For “undruggable” viral proteins, the development of bivalent degraders (PROTACs) may be a more tractable process than development of functional inhibitors
